Pacira BioSciences, Inc.

https://www.pacira.com

Pacira BioSciences, Inc. is a pharmaceutical company specializing in the development and commercialization of non-opioid pain management and regenerative health solutions. The company's mission is to deliver innovative, non-opioid pain therapies to transform the lives of patients, aiming to redefine the role of opioids as rescue therapy only. Its corporate headquarters are located in Tampa, Florida.

Pacira's product portfolio includes three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release intra-articular injection for osteoarthritis knee pain; and iovera, a handheld cryoanalgesia device for drug-free pain control. These products leverage the company's proprietary multivesicular liposome (pMVL) technology for sustained drug release. Pacira primarily serves healthcare practitioners and institutions, including hospitals, ambulatory surgical centers, and orthopedic clinics, within the United States.

In recent developments, Pacira BioSciences reported total revenues of $177.4 million for the first quarter of 2026, marking a 5% increase year-over-year. The company is actively advancing its pipeline, having completed enrollment in a Phase 3 study for ZILRETTA in shoulder osteoarthritis and progressing a Phase 2 study for PCRX-201, a gene therapy for knee osteoarthritis, with top-line data anticipated later in 2026. Frank D. Lee serves as the Chief Executive Officer and Director. Pacira maintains a market leadership position in non-opioid pain management, driven by its "5x30 strategy" launched in January 2025, which aims to treat over 3 million patients annually and achieve double-digit product revenue growth by 2030.

Latest updates

Pacira BioSciences Posts Modest Revenue Growth, Pipeline Data Drives Outlook

Event summary

  • Pacira BioSciences reported Q1 2026 revenue of $177 million, a 5% increase year-over-year.
  • The company completed enrollment in Phase 3 trials for ZILRETTA in osteoarthritis pain of the shoulder, anticipating topline results by year-end.
  • EXPAREL sales grew by 5% to $143.3 million, partially offset by discounting related to a GPO partnership.
  • Pacira repurchased 2.2 million shares for $50 million during Q1 2026, leaving $100 million remaining on the authorization.

The big picture

Pacira's modest revenue growth, while positive, highlights the challenges of maintaining momentum in a competitive pain management market. The company's focus on real-world evidence and clinical innovation, particularly with ZILRETTA and PCRX-201, represents a strategic shift towards higher-value, differentiated therapies. The ongoing share repurchase program signals management's confidence in the company's long-term prospects, but hinges on successful clinical outcomes and market adoption.

What we're watching

Clinical Trial Risk
The success of the ZILRETTA Phase 3 trial is critical for Pacira’s long-term growth strategy, and a negative outcome could significantly impact investor sentiment.
Market Dynamics
The impact of discounting related to the GPO partnership on EXPAREL sales will need to be monitored closely to assess the sustainability of revenue growth.
Pipeline Progression
The timing and results of the Phase 2 study for PCRX-201 will be key indicators of Pacira’s ability to expand its product portfolio and address unmet needs in osteoarthritis treatment.

Pacira BioSciences Battles Proxy Contest, Defends Growth Strategy

Event summary

  • Pacira BioSciences has filed definitive proxy materials for its June 9, 2026, Annual Meeting, urging shareholders to vote for its nominated board members.
  • The company is facing a proxy contest from DOMA Perpetual Capital Management, which has nominated its own slate of directors.
  • Pacira’s board claims DOMA’s nominees lack relevant biopharmaceutical industry experience and expertise.
  • Pacira’s stock has risen over 35% since the launch of its ‘5x30’ strategy, which aims to drive long-term value.
  • Pacira returned $200 million to shareholders through share repurchases in 2025 and 2026.

The big picture

Pacira's proxy battle highlights the growing trend of activist investors targeting biopharma companies, often focusing on perceived undervaluation and strategic direction. DOMA's challenge suggests a lack of confidence in Pacira’s current management and their ability to deliver on the ambitious ‘5x30’ plan. The outcome will likely set a precedent for shareholder activism within the sector, particularly concerning long-term growth strategies and capital allocation.

What we're watching

Governance Dynamics
The outcome of the proxy contest will reveal the extent of shareholder support for Pacira’s current strategy and board composition, potentially impacting future governance decisions.
Execution Risk
The success of Pacira’s ‘5x30’ strategy hinges on continued operational progress and market adoption of its products, and any setbacks could undermine investor confidence.
IP Protection
The ongoing patent litigation surrounding EXPAREL will be a key factor in determining Pacira’s long-term revenue potential and ability to defend its market position.

EXPAREL Data Links Reduced Opioid Use to Lower Healthcare Costs for Hip Arthroplasty Patients

Event summary

  • A retrospective study analyzing Medicare patient data found EXPAREL® associated with significant reductions in opioid use (up to 637 MMEs at 90 days) following total hip arthroplasty.
  • Patients receiving EXPAREL experienced lower healthcare utilization, including fewer inpatient admissions (42 vs 79 at 30 days) and emergency department visits (673 vs 639 at 30 days).
  • Total medical costs were significantly lower for EXPAREL patients compared to those receiving standard care (e.g., $1233 vs $1627 at 30 days).
  • The data was presented at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting on April 16-18, 2026.
  • The study analyzed data up to 365 days post-surgery, demonstrating sustained reductions in opioid use and healthcare costs.

The big picture

Pacira's EXPAREL is positioned to benefit from the ongoing push to reduce opioid dependence in surgical settings, particularly among vulnerable Medicare populations. The study’s findings on reduced healthcare costs provide a compelling economic argument for wider adoption, potentially displacing standard-of-care options and generating significant revenue for Pacira. However, the company faces ongoing pressure to demonstrate long-term clinical efficacy and manage potential pricing headwinds from payers.

What we're watching

Market Adoption
The pace at which EXPAREL adoption expands within the broader orthopedic surgery market will depend on reimbursement policies and physician education regarding its benefits.
Competitive Dynamics
How competitors respond to EXPAREL’s demonstrated cost savings and reduced opioid usage will shape the long-term market landscape for regional anesthesia.
Regulatory Scrutiny
Increased scrutiny from CMS and other payers regarding opioid usage and associated healthcare costs could accelerate EXPAREL adoption, but also introduce pricing pressures.

Pacira Data Suggests EXPAREL Drives Cost Savings in Outpatient Arthroplasty

Event summary

  • Pacira BioSciences presented three real-world studies at the AMCP Annual 2026 Meeting demonstrating lower total healthcare costs associated with EXPAREL use in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) procedures.
  • One study found lower healthcare costs (3-month: $7,332 vs $8,153; 6-month: $13,022 vs $15,081) and reduced opioid utilization in Medicare Advantage beneficiaries undergoing THA with EXPAREL.
  • A three-year budget impact analysis projected cumulative cost savings of $117,868 per 1 million members by year 3 compared to ropivacaine in Commercial and Medicare Advantage settings.
  • In teaching hospitals, EXPAREL use was associated with lower adjusted costs at all evaluated time points, with pharmacy costs significantly lower on the day of surgery.

The big picture

Pacira's data reinforces the growing trend towards value-based care and opioid-sparing pain management solutions within the orthopedic surgery space. The findings suggest EXPAREL can offer a compelling economic argument for payers seeking to reduce overall healthcare expenditures while addressing the opioid crisis. The $117,868 projected savings, while dependent on model assumptions, represents a potentially significant opportunity for Pacira to expand its market share and solidify its position as a leader in non-opioid pain therapies.

What we're watching

Market Adoption
The pace at which these cost savings findings translate into broader adoption of EXPAREL within hospital outpatient departments will depend on payer coverage decisions and physician acceptance.
Competitive Response
Ropivacaine manufacturers and other pain management solution providers will likely attempt to counter Pacira’s claims and highlight any limitations in the presented data.
Regulatory Scrutiny
Continued emphasis on opioid stewardship may lead to increased regulatory scrutiny of EXPAREL's use and require Pacira to proactively address any concerns regarding long-term patient outcomes.

Pacira Sweetens New Hire Packages with Equity Grants

Event summary

  • Pacira BioSciences will host an analyst-led fireside chat on April 15, 2026, at 9:30 AM ET.
  • The company granted inducement awards totaling 18,000 shares to nine new employees on April 2, 2026.
  • Two employees received stock options (5,000 shares) and seven received restricted stock units (13,000 shares).
  • Stock options have an exercise price of $22.70 per share, reflecting the closing price on the grant date.
  • The equity awards vest over four years, with the first 25% vesting on April 1, 2027.

The big picture

Pacira's inducement awards, while compliant with Nasdaq rules, highlight the ongoing challenge of attracting and retaining talent in the biotech sector. The grants, totaling 18,000 shares, represent a notable commitment of equity, and the reliance on such inducements may signal difficulties in securing talent through salary alone. This practice is increasingly common as companies compete for specialized skills, but it also introduces potential dilution concerns for existing shareholders.

What we're watching

Compensation Trends
The size of the equity grants, particularly the RSUs, suggests Pacira is facing pressure to attract talent in a competitive market, potentially impacting operating expenses.
Shareholder Scrutiny
While Nasdaq rules allow these grants without shareholder approval, continued reliance on inducement awards could draw scrutiny from investors concerned about dilution and executive compensation.
Execution Risk
The vesting schedule tied to continued employment underscores the importance of integrating these new hires and ensuring they contribute to Pacira’s pipeline and commercial goals.

Pacira Data Shows EXPAREL Reduces Orthopaedic Care Costs

Event summary

  • Pacira BioSciences presented real-world data at the Orthopaedic Research Society 2026 Annual Meeting demonstrating reduced total cost of care for EXPAREL® in total knee arthroplasty (TKA) and spinal fusion procedures.
  • Studies, using propensity score matching, showed EXPAREL associated with lower costs compared to ropivacaine and standard of care options.
  • The spinal fusion study found reductions primarily driven by a shorter length of hospital stay, with cost savings of approximately $6,000 per patient.
  • One TKA study showed cost reductions of $409 in commercial cohorts and $1,359 in Medicare Advantage cohorts.

The big picture

Pacira's data reinforces the trend towards non-opioid pain management solutions, driven by regulatory pressure and patient preference. The demonstrated cost savings of EXPAREL, particularly in inpatient settings, could accelerate adoption by hospitals seeking to reduce expenses and improve patient outcomes. This data provides a tangible economic argument for EXPAREL, potentially expanding its use beyond current indications and increasing its overall market share within the $10 billion orthopaedic pain management market.

What we're watching

Market Adoption
The pace at which these cost-savings findings are disseminated and adopted by hospital systems and surgeons will determine EXPAREL’s continued market penetration and revenue growth.
Competitive Response
How ropivacaine manufacturers and other pain management solution providers react to this data, and whether they attempt to counter with their own studies or pricing strategies, will shape the competitive landscape.
Regulatory Scrutiny
The NOPAIN Act’s potential impact on opioid prescribing and the broader regulatory environment for non-opioid pain management therapies will continue to influence Pacira’s market access and reimbursement rates.

Pacira BioSciences Faces Proxy Fight as DOMA Challenges Board

Event summary

  • Pacira BioSciences is facing a proxy contest, with DOMA Perpetual Capital Management nominating three director candidates.
  • DOMA's nomination comes after 12 meetings with Pacira's Board and management, with no new strategic insights shared.
  • Pacira touts progress on its '5x30' strategy, including 6.2% EXPAREL volume growth in 2025 and record gross margins of 81%.
  • Pacira executed $150 million in common stock repurchases in 2025, reducing outstanding shares from 47 million to 41 million.
  • The 2026 Annual Meeting date has not been announced, and no shareholder action is required at this time.

The big picture

The proxy fight highlights a growing trend of activist investors targeting biopharma companies, particularly those perceived as underperforming or lacking clear strategic direction. DOMA's challenge suggests a lack of confidence in Pacira's current management and board's ability to unlock shareholder value, despite the company's claims of progress. The outcome will likely set a precedent for future shareholder activism within the pain management sector.

What we're watching

Governance Dynamics
The outcome of the proxy contest will reveal the extent of shareholder dissatisfaction with Pacira’s current strategy and board composition, potentially influencing future governance decisions.
Execution Risk
Pacira's ability to deliver on the ambitious goals outlined in its '5x30' strategy will be critical, and any setbacks could embolden activist investors.
Pipeline Progress
The upcoming data releases for PCRX-201 and iovera will be key catalysts for the stock, and their success will determine the long-term viability of Pacira’s pipeline.

Pacira to Detail Strategy at Barclays Healthcare Conference

Event summary

  • Pacira BioSciences will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference.
  • The event is scheduled for March 11, 2026, at 2:30 PM ET in Miami.
  • A live audio webcast will be available on Pacira's investor relations website.
  • Pacira's product portfolio includes EXPAREL®, ZILRETTA®, and iovera®º.

The big picture

Pacira's participation in the Barclays conference signals a continued effort to engage with investors and analysts amidst ongoing scrutiny of the opioid crisis and the demand for alternative pain management solutions. The fireside chat offers a platform to address investor concerns regarding the company's pipeline, market positioning, and long-term growth prospects. The company's valuation will be heavily influenced by the perceived success of its gene therapy program and its ability to maintain market leadership in non-opioid pain therapies.

What we're watching

Pipeline Progress
The conference provides an opportunity to assess the progress of PCRX-201, Pacira’s gene therapy candidate, and whether Phase 2 data will support continued development.
Market Adoption
How effectively Pacira can articulate the value proposition of its non-opioid therapies will influence adoption rates and ultimately impact revenue growth in a competitive pain management landscape.
Competitive Landscape
The discussion will likely reveal the extent to which emerging competitors are impacting Pacira’s market share and pricing power within the regional and specialty anesthesia segments.

Pacira Data Shows Real-World Benefit of Non-Opioid Pain Therapies

Event summary

  • Pacira BioSciences presented two real-world studies from its Innovations in Genicular Outcomes Registry (IGOR) at the AAOS 2026 Annual Meeting.
  • One study demonstrated EXPAREL® was associated with improved pain, opioid use, function, and length of stay after total knee arthroplasty (TKA).
  • The second study showed ioveraº treatment associated with longer-term pain and function improvement (up to 12 months) compared to typical alternatives.
  • The EXPAREL study involved 42 patients receiving liposomal bupivacaine versus 183 receiving conventional anesthetics, showing statistically significant pain score reductions.

The big picture

Pacira’s IGOR registry highlights the growing demand for non-opioid pain management solutions, driven by regulatory pressure and patient preference. The registry’s findings provide valuable data to support the clinical effectiveness of Pacira’s therapies, potentially accelerating adoption and expanding market reach. However, the company faces ongoing competition and the need to continually demonstrate the value proposition of its products in a rapidly evolving healthcare landscape.

What we're watching

Market Adoption
The pace at which IGOR data influences adoption of EXPAREL and ioveraº within orthopedic practices will determine Pacira’s revenue growth trajectory.
Regulatory Scrutiny
Increased reliance on real-world evidence may draw greater scrutiny from the FDA and EMA regarding the long-term efficacy and safety of Pacira’s therapies.
Competitive Landscape
How competitors respond to Pacira’s IGOR data and develop alternative non-opioid pain management solutions will shape the long-term market share dynamics.

Pacira BioSciences Posts Record EXPAREL Sales, Eyes Asian Expansion

Event summary

  • Pacira BioSciences reported Q4 2025 revenues of $196.9 million, a 5% increase year-over-year, driven by record EXPAREL sales.
  • Full-year 2025 revenues reached $726.4 million, a 4% increase compared to 2024.
  • The company entered into a strategic partnership with LG Chem to commercialize EXPAREL in select Asian-Pacific markets, receiving an upfront payment.
  • Pacira repurchased 2.0 million shares in Q4 2025, totaling 5.9 million shares repurchased for the full year at a cost of $150 million.

The big picture

Pacira’s reliance on EXPAREL for the majority of its revenue creates a concentration risk. The partnership with LG Chem represents an attempt to diversify geographically and mitigate this risk, but success is not guaranteed. The company’s aggressive share repurchase program signals confidence in its current valuation, but also limits capital available for R&D or acquisitions.

What we're watching

Market Penetration
The success of the LG Chem partnership will hinge on navigating regulatory hurdles and establishing distribution networks in the Asian-Pacific region, potentially impacting Pacira’s overall growth trajectory.
Patent Protection
Continued patent protection for EXPAREL remains critical, as generic competition could significantly erode market share and pricing power, impacting future revenue projections.
R&D Pipeline
The progress and eventual commercialization of PCRX-201, Pacira’s gene therapy candidate, will be a key determinant of long-term growth and diversification beyond EXPAREL.

NOPAIN Act Data Shows Early Adoption, Boosts Pacira's Non-Opioid Push

Event summary

  • A survey of 750 hospital and ASC directors found 85% were aware of the NOPAIN Act.
  • 52% of facilities surveyed have taken steps to increase the use of non-opioid pain management options.
  • 83% of respondents reported decreased opioid prescribing immediately after surgery, and 88% at discharge.
  • The NOPAIN Act went into effect on January 1, 2025, as part of the Consolidated Appropriations Act of 2023.

The big picture

The NOPAIN Act represents a significant shift in pain management practices, driven by mounting pressure to address the opioid crisis. Pacira, as a leading provider of non-opioid alternatives, is positioned to benefit from this regulatory tailwind, but its success hinges on broader adoption across the healthcare system and sustained clinical efficacy.

What we're watching

Commercial Adoption
While Medicare adoption is evident, the pace at which commercial payers follow suit will be critical for Pacira's long-term revenue growth and market penetration.
Protocol Shifts
The sustainability of the reported protocol changes within hospitals and ASCs will depend on ongoing education, reimbursement models, and potential resistance from surgeons or anesthesiologists.
Competitive Landscape
How other non-opioid pain management companies respond to the NOPAIN Act and Pacira's market position will shape the competitive dynamics within the sector.

Pacira Adds Seasoned Pharma Exec to Board Amid Gene Therapy Push

Event summary

  • Pacira BioSciences appointed Samit Hirawat, M.D., to its Board of Directors, increasing the board size to 10 members.
  • Dr. Hirawat previously served as Chief Medical Officer and Executive Vice President at Bristol Myers Squibb, and held leadership roles at Novartis Pharmaceuticals.
  • He brings over 25 years of clinical development and industry expertise to Pacira.
  • Dr. Hirawat’s experience includes overseeing global clinical development portfolios and advancing therapies across therapeutic areas, including oncology.

The big picture

Pacira’s move to bolster its board with a clinical development expert underscores the increasing importance of gene therapies in pain management and the competitive pressure within the non-opioid pain treatment market. The appointment suggests a desire to accelerate the development and commercialization of innovative therapies, potentially signaling a broader strategic pivot beyond its existing portfolio. This also highlights the ongoing trend of biopharma companies seeking experienced leadership to navigate complex regulatory landscapes and drive pipeline innovation.

What we're watching

Governance Dynamics
The addition of a seasoned executive like Dr. Hirawat signals a potential shift in Pacira’s strategic direction, particularly given his experience with gene therapies, and warrants monitoring of how his influence shapes the company’s pipeline decisions.
Pipeline Execution
Dr. Hirawat’s focus on clinical development will be critical as Pacira advances PCRX-201 and other pipeline assets; the speed and success of these trials will be key indicators of the board’s effectiveness.
Market Positioning
Pacira’s stated ambition to ‘fundamentally transform how pain is treated’ requires a significant market shift; tracking adoption rates of existing and future therapies will reveal whether the company can truly disrupt the pain management landscape.

Pacira Expands Asian Footprint with LG Chem Distribution Deal

Event summary

  • Pacira BioSciences has partnered with LG Chem to distribute EXPAREL® in select Asian-Pacific markets.
  • LG Chem secures exclusive commercialization rights for EXPAREL® in the licensed territories.
  • Pacira will manufacture EXPAREL®, while LG Chem handles regulatory approvals and market entry.
  • LG Chem plans to file for marketing authorizations in South Korea and Thailand within six months.
  • Pacira will receive an undisclosed upfront payment, transfer pricing, and tiered royalties.

The big picture

This partnership represents Pacira’s continued push to expand EXPAREL’s global reach beyond its established North American market. LG Chem’s existing orthopedic pain management infrastructure provides Pacira with a shortcut to market penetration in a region with significant unmet needs for non-opioid pain control, but also introduces reliance on a third party for commercial execution. The deal’s financial terms remain opaque, making it difficult to assess the true value of the arrangement.

What we're watching

Regulatory Hurdles
The speed of regulatory approvals in South Korea and Thailand will be a key indicator of the partnership's success and LG Chem’s execution capabilities.
Market Adoption
How quickly EXPAREL gains traction within the Asian-Pacific market, particularly given existing analgesic preferences, will determine the financial upside for both Pacira and LG Chem.
Financial Impact
The undisclosed upfront payment and tiered royalty structure will need to be substantial to justify the ceded exclusivity and offset Pacira’s manufacturing costs.

Pacira to Present at J.P. Morgan Healthcare Conference Amidst Pain Management Shift

Event summary

  • Pacira BioSciences will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
  • The presentation will occur at 11:15 AM PST (2:15 PM EST).
  • A live audio webcast will be available on Pacira’s investor relations website.
  • Pacira's product portfolio includes EXPAREL®, ZILRETTA®, and iovera®º.
  • PCRX-201, a gene therapy for osteoarthritis, is in Phase 2 clinical development.

The big picture

Pacira’s presence at J.P. Morgan underscores the ongoing shift towards non-opioid pain management solutions, driven by regulatory pressure and patient demand. The company's portfolio, while established, faces increasing competition and scrutiny regarding long-term efficacy and cost-effectiveness. The conference presentation offers a crucial opportunity to address these concerns and reaffirm investor confidence.

What we're watching

Pipeline Progress
The conference presentation will likely detail progress on PCRX-201, and investor sentiment will hinge on Phase 2 data and the potential for a faster path to market than competing therapies.
Competitive Landscape
How Pacira addresses increasing competition in the non-opioid pain management space, particularly with the emergence of novel therapies and delivery methods, will be a key indicator of long-term market share.
Reimbursement Risk
The sustainability of current reimbursement rates for Pacira’s core products will depend on demonstrating continued clinical value and navigating potential changes in payer policies.

Pacira Data Shows iovera° Outperforms RFA in Chronic Back Pain Study

Event summary

  • A randomized pilot study published in *Pain Physician* compared Pacira BioSciences’ iovera° cryoneurolysis to radiofrequency ablation (RFA) for chronic low back pain (CLBP).
  • Patients treated with iovera° demonstrated significantly lower pain scores (3.1 vs. 5.4 at 180 days, 3.0 vs. 6.1 at 360 days) and improved functional disability (ODI scores of 10.1 vs. 20.6 at 360 days) compared to RFA.
  • The study reported that 45.5% of iovera° patients versus 75% of RFA patients required additional spine injections after 180 days.
  • No treatment-related adverse events were reported in either group.
  • Pacira recently received FDA clearance for a new ‘SmartTip’ designed to allow deeper nerve access for lumbar applications.

The big picture

Chronic low back pain represents a substantial economic burden in the U.S., driving opioid use and disability claims. Pacira’s iovera° offers a non-opioid alternative to RFA, a standard treatment with potential tissue damage. The pilot study’s positive results, while preliminary, suggest iovera° could capture a portion of this large market, but broader adoption hinges on larger, more definitive clinical trials and favorable reimbursement.

What we're watching

Clinical Adoption
The pace of adoption of iovera° by clinicians will depend on broader acceptance of cryoneurolysis as a viable alternative to RFA, particularly given the pilot study’s small sample size.
Regulatory Pathway
Further clinical evidence and FDA approvals for expanded indications will be critical for Pacira to meaningfully penetrate the chronic low back pain market, which represents a significant unmet need.
Competitive Landscape
The emergence of competing cryoneurolysis technologies or alternative pain management solutions could erode iovera°’s market share and limit Pacira’s revenue growth.
CID: 234